–
Spyre Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−65.6
FY22:
−84.8
FY23:
−242
FY24:
−209
FY25:
−210
(positive)
Change from FY21 to FY24
millions USD
FY21:
−64.1
FY22:
−83.2
FY23:
–
FY24:
−209
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−65.7
FY22:
−84.0
FY23:
−339
FY24:
−208
FY25:
−155
(positive)
Change from FY21 to FY25
millions USD
FY21:
−65.8
FY22:
−83.8
FY23:
−339
FY24:
−208
FY25:
−155
All amounts in millions USD